Cefuroxime axetil – wide spectrum of indications. Why is it worth it? Review article

Main Article Content

Adam J. Sybilski

Abstract

Cefuroxime axetil is a prodrug – acetoxyethyl ester of cefuroxime, intended for oral administration. In vitro, the drug exhibits a broad spectrum of antibacterial activity. It is active against Gram-positive aerobic bacteria, Gram-negative aerobic bacteria and spirochetes (Borrelia burgdorferi). The broad spectrum of antibacterial activity means that cefuroxime axetil can be used in many indications in both adults and children. The diseases in which this antibiotic is recommended include: acute streptococcal pharyngitis and tonsillitis, bacterial sinusitis, acute otitis media, lower respiratory tract infections, urinary tract infection in the lower urinary tract, pyelonephritis, uncomplicated skin and soft tissue infections, bone and joint infections, early Lyme disease and perioperative prophylaxis. In adults, a single dose is 250–500 mg, in the pediatric population, the dosage depends on the child’s body weight, usually 10–15 mg/kg b.w. Cefuroxime is administered as a prodrug, so it disrupts the natural balance of intestinal microflora to a lesser extent – there is a lower risk of post-antibiotic diarrhea. There are no clinically significant interactions with other drugs. The availability of various preparations, easy dosing and relatively low price mean that cefuroxime axetil can be successfully used in many patients of different ages.

Article Details

How to Cite
Sybilski, A. J. (2024). Cefuroxime axetil – wide spectrum of indications. Why is it worth it?. Medycyna Faktow (J EBM), 17(4(65), 471-474. https://doi.org/10.24292/01.MF.0424.06
Section
Articles

References

1. Kozikowska K, Sybilski AJ. Aksetyl cefuroksymu w ujęciu praktycznym. Świat Med. Farm. 2019; 212 (1): 112-6.
2. Perry CM, Brogden RN. Cefuroxime Axetil: A Review of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Efficacy. Drugs. 1996; 52: 125-58.
3. Faísca F, Petrovski Ž, Grilo I et al. Synthesis, Characterization, Bioavailability and Antimicrobial Studies of Cefuroxime-Based Organic Salts and Ionic Liquids. Pharmaceutics. 2024; 16(10): 1291.
4. O’Callaghan CH, Sykes RB, Griffiths A et al Cefuroxime, a new cephalosporin antibiotic: Activity in vitro. Antimicrob Agents Chemother. 1976; 9: 511-9.
5. Hryniewicz W, Albrecht P, Radzikowski A. Rekomendacje postępowania w pozaszpitalnych zakażeniach układu oddechowego. Narodowy Program Ochrony Antybiotyków. Warszawa 2016.
6. Anon JB, Jacobs MR, Poole MD et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 2004; 130(1 Suppl): 1-45.
7. Lin H, Jia Y, Kong X et al. In Vivo Evaluation of Cefuroxime Axetil-Loaded Bioadhesive Nanoparticles to Treat Haemophilus influenzae-Induced Otitis Media. Front Bioeng Biotechnol. 2022; 10: 884797.
8. Scott LJ, Ormrod D, Goa KL. Cefuroxime axetil: an updated review of its use in the management of bacterial infections. Drugs. 2001; 61(10): 1455-500.
9. Hennaut E, Duong HP, Chiodini B et al. Prospective Cohort Study Investigating the Safety and Efficacy of Ambulatory Treatment With Oral Cefuroxime-
Axetil in Febrile Children With Urinary Tract Infection. Front Pediatr. 2018; 6: 237.
10. Dellamonica P. Cefuroxime axetil. Int J Antimicrob Agents. 1994; 4(1): 23-36.
11. Jaulhac B, Saunier A, Caumes E et al. Lyme borreliosis and other tick-borne diseases. Guidelines from the French scientific societies (II). Biological diagnosis, treatment, persistent symptoms after documented or suspected Lyme borreliosis. Med Mal Infect. 2019; 49(5): 335-46.
12. Pancewicz SA, Garlicki AM, Moniuszko-Malinowska A et al. Diagnosis and treatment of tick-borne diseases. Recommendations of the Polish Society of Epidemiology and Infectious Diseases. Przegl Epidemiol. 2015; 69: 309-16.
13. Torbahn G, Hofmann H, Rücker G et al. Efficacy and Safety of Antibiotic Therapy in Early Cutaneous Lyme Borreliosis: A Network Meta-analysis. JAMA Dermatol. 2018; 154(11): 1292-303.
14. Hryniewicz W, Kulig J, Ozorowski T et al. Stosowanie antybiotyków w profilaktyce okołooperacyjnej, Narodowy Program Ochrony Antybiotyków, Warszawa 2011.
15. Charakterystyka Produktu Leczniczego. Biotracef.